Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.50 |
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23834257 | 0.87 | TAS1R3 (0.49) | TAS1R3TAS1R1APLNRCD274PDCD1 | |
| SCHEMBL2248442 | 0.86 | TAS1R3 (0.50) | TAS1R3TAS1R1APLNRCD274PDCD1 | |
| SCHEMBL2247336 | 0.84 | ITGA4 (0.53) | MEN1KMT2A | |
| SCHEMBL28047753 | 0.84 | PTPN1 (0.45) | CD274PDCD1 | |
| SCHEMBL28047760 | 0.84 | PTPN1 (0.45) | CD274PDCD1 | |
| SCHEMBL28662643 | 0.84 | APLNR (0.55) | TAS1R3TAS1R1APLNRCD274PDCD1 | |
| SCHEMBL28662641 | 0.84 | APLNR (0.55) | TAS1R3TAS1R1APLNRCD274PDCD1 | |
| SCHEMBL29233269 | 0.83 | TAS1R3 (0.54) | TAS1R3TAS1R1APLNRCD274PDCD1 | |
| SCHEMBL2242522 | 0.81 | MMP2 (0.48) | — | |
| SCHEMBL2248276 | 0.80 | MEN1 (0.51) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | TAS1R3 1826/4885TAS1R1 1668/4885APLNR 127/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | TAS1R3 1826/4885TAS1R1 1668/4885APLNR 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.